Pakistan, Uzbekistan explore collaboration

Commerce minister visits Tashkent Pharma Park to strengthen ties in healthcare


APP March 02, 2025
PHOTO: RADIO PAKISTAN

print-news
Listen to article
ISLAMABAD:

Federal Minister for Commerce, Jam Kamal Khan, on Saturday paid an official visit to Tashkent Pharma Park in a bid to explore potential avenues for cooperation between Pakistan and Uzbekistan in the pharmaceutical sector.

Accompanying the minister on this visit was Uzbekistan's Minister of Investment, Industry, and Trade, Laziz Kudratov, along with Ata Ullah, the Trade and Investment Counsellor at the Embassy of Pakistan. The delegation was warmly received upon arrival by Abdulla Azizov, Chairman of the Pharm Agency Uzbekistan, who provided them with a comprehensive briefing on the park's history, key achievements, and the extensive facilities available to support pharmaceutical industries.

During the visit, Minister Jam Kamal Khan toured various departments of the pharma park, gaining valuable insights into its state-of-the-art infrastructure, advanced research capabilities, and cutting-edge technological developments. He highlighted that the park presents a significant opportunity for collaboration with Pakistani medical universities and the herbal medicine industry. He also stressed the importance of strengthening bilateral ties in the healthcare and pharmaceutical sectors to enhance joint research initiatives, boost production capabilities, and facilitate increased trade between the two nations.

As part of his visit, the minister also inspected the park's warehouse facility, where he reviewed its modern storage and logistics capabilities, which play a crucial role in the efficient distribution of pharmaceutical products.

The visit reaffirmed Pakistan's commitment to fostering stronger trade and investment relations with Uzbekistan, particularly in the rapidly growing pharmaceutical sector.

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ